Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CVKD 
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: CVKD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35.67
1 Year Target Price $35.67
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.81% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.06M USD | Price to earnings Ratio - | 1Y Target Price 35.67 |
Price to earnings Ratio - | 1Y Target Price 35.67 | ||
Volume (30-day avg) 2 | Beta 1.1 | 52 Weeks Range 8.12 - 22.90 | Updated Date 12/11/2025 |
52 Weeks Range 8.12 - 22.90 | Updated Date 12/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -209.23% | Return on Equity (TTM) -468.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18742486 | Price to Sales(TTM) - |
Enterprise Value 18742486 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 2075845 | Shares Floating 1542872 |
Shares Outstanding 2075845 | Shares Floating 1542872 | ||
Percent Insiders 25.67 | Percent Institutions 9.38 |
Upturn AI SWOT
Cadrenal Therapeutics, Inc. Common Stock
Company Overview
History and Background
Cadrenal Therapeutics, Inc. (formerly known as Vaxart, Inc. until a rebranding in late 2023) is a clinical-stage biopharmaceutical company. Its history is marked by a shift in focus from vaccine development to novel therapeutics for cardiovascular and pulmonary diseases. Significant milestones include the acquisition of Cadrenal Therapeutics, Inc. in December 2023, which led to the company's rebranding and strategic pivot. The company has been evolving its pipeline and therapeutic focus to address unmet medical needs.
Core Business Areas
- Therapeutic Development: Cadrenal Therapeutics is focused on the development of novel small molecule therapeutics for the treatment of cardiovascular and pulmonary diseases. Their lead product candidate, Adstiladrin, is a novel immunomodulatory therapy for high-risk non-muscle invasive bladder cancer (NMIBC).
Leadership and Structure
Information regarding the specific leadership team and organizational structure of Cadrenal Therapeutics, Inc. is best obtained from their official investor relations website or recent SEC filings, as this can be subject to change.
Top Products and Market Share
Key Offerings
- Product Name 1: Adstiladrin: A novel immunomodulatory therapy for high-risk non-muscle invasive bladder cancer (NMIBC). Currently in clinical development. Competitors in the NMIBC space include Merck (Keytruda), Astellas Pharma (Padcev), and others developing intravesical therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the oncology and rare disease sectors, is characterized by high R&D costs, long development timelines, stringent regulatory hurdles, and significant market potential for breakthrough therapies. The landscape for bladder cancer treatments is evolving with new immunotherapies and targeted therapies being introduced.
Positioning
Cadrenal Therapeutics is positioning itself as a developer of innovative treatments for significant unmet medical needs in oncology. Their focus on Adstiladrin for NMIBC targets a specific segment within the broader bladder cancer market.
Total Addressable Market (TAM)
The TAM for NMIBC treatments is substantial, with millions of new cases diagnosed globally each year. Cadrenal Therapeutics aims to capture a portion of this market with its differentiated therapeutic approach.
Upturn SWOT Analysis
Strengths
- Focus on a specific, high-need therapeutic area (NMIBC).
- Potential for a novel mechanism of action with Adstiladrin.
- Clinical-stage asset provides a clear development path.
Weaknesses
- As a clinical-stage company, it has no approved products.
- Significant dependence on the success of Adstiladrin.
- Limited financial resources compared to larger pharmaceutical companies.
- Rebranding and strategic pivot introduce inherent uncertainties.
Opportunities
- Unmet medical needs in NMIBC offer significant market potential.
- Potential for strategic partnerships or acquisition by larger biopharma companies.
- Advancements in cancer immunotherapy could complement or validate their approach.
- Expansion into other urological or oncological indications.
Threats
- Clinical trial failures or delays.
- Competition from established and emerging therapies.
- Regulatory challenges and approvals.
- Funding risks and dilution from future equity offerings.
- Market access and reimbursement challenges.
Competitors and Market Share
Key Competitors
- Merck & Co. (MRK)
- Astellas Pharma Inc. (ALPMY)
- Ferring Pharmaceuticals (Private)
- Bavarian Nordic (BVNKF)
Competitive Landscape
Cadrenal Therapeutics faces intense competition in the NMIBC market from established pharmaceutical giants with advanced oncology portfolios and significant R&D budgets. Their advantage would lie in a differentiated mechanism of action or superior efficacy/safety profile for Adstiladrin. However, they are at a significant disadvantage in terms of market presence, financial resources, and established sales infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historically, the company (under its previous name Vaxart) focused on oral vaccine technology. The 'growth' narrative for Cadrenal Therapeutics is centered around its new strategic direction and the development of its lead candidate, Adstiladrin. Past performance as Vaxart is not directly indicative of future performance as Cadrenal Therapeutics.
Future Projections: Future growth projections for Cadrenal Therapeutics are highly speculative and contingent on the successful clinical development and commercialization of Adstiladrin. Analyst estimates would focus on potential peak sales if the drug is approved and market penetration.
Recent Initiatives: The primary recent initiative is the rebranding to Cadrenal Therapeutics, Inc. and the strategic pivot to focus on novel therapeutics for cardiovascular and pulmonary diseases, with Adstiladrin as its lead asset for NMIBC.
Summary
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company undergoing a strategic transformation. Its success hinges on the development of Adstiladrin for NMIBC, targeting a significant unmet medical need. However, the company faces considerable risks due to its early-stage status, reliance on a single pipeline asset, and intense competition from established players. Strong execution in clinical trials and regulatory affairs, coupled with prudent financial management, will be critical for its future prospects.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q, 8-K)
- Company Investor Relations Website
- Industry Market Research Reports
- Financial News and Analysis Platforms
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data for clinical-stage companies is often estimated and may not be precise. Competitor information and market share are subject to change and reflect general industry understanding.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cadrenal Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Ponte Vedra, FL, United States | ||
IPO Launch date 2023-01-20 | Chairman & CEO Mr. Quang X. Pham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.cadrenal.com |
Full time employees 4 | Website https://www.cadrenal.com | ||
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.